-
121
Impact of COVID-19 vaccination on tinnitus onset and severity: a comprehensive survey study
Published 2025-02-01“…There was no significant difference in tinnitus onset latency between mRNA vaccines (Pfizer and Moderna) and non-mRNA vaccines (Johnson & Johnson). …”
Get full text
Article -
122
-
123
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Published 2025-01-01“…For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 (“COVID-19”) and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. …”
Get full text
Article -
124
Traditional Chinese acupuncture versus minimal acupuncture for mild-to-moderate knee osteoarthritis: a protocol for a randomised, controlled pilot trial
Published 2016-12-01“…Secondary end points include pain and function measurement, global change, the quality of life and the use of non-steroidal anti-inflammatory drugs (Celebrex, Pfizer) at 8, 16 and 26 weeks.Ethics and dissemination Ethical approval of this study has been granted by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (permission number: 2016BL-010-02). …”
Get full text
Article -
125
Papel del Estado en la campaña de vacunación contra la COVID-19 a través del ordenamiento jurídico
Published 2024-04-01“…Durante el proceso de emergencia, las vacunas que aprobaron las autoridades para la población fueron las Pfizer-BioNTech, Moderna, Sputnik, Jhonson & Jhonson, AstraZeneca, Sinopharm, Sinovac, Covaxin y Covocax. …”
Get full text
Article -
126
COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?
Published 2021-07-01“…Case Reports: The first patient was a 79-year-old female was presented to us 35 days after a sudden bilateral loss of vision, which occurred two days after receiving the second recombinant mRNA vaccine (Pfizer) injection. Temporal artery biopsy was compatible with AAION. …”
Get full text
Article -
127
-
128
-
129
The effect of meningococcal vaccines on new generation of systemic inflammatory markers in children
Published 2025-01-01“…The data of those who received the first 2 doses at 2-month intervals and the next dose between 8–12 months were included. Nimenrix® (Pfizer) administered as a single dose to children from 12 months of age. …”
Get full text
Article -
130
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
Published 2019-01-01Get full text
Article -
131
A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus
Published 2025-02-01“…Abstract The Food and Drug Administration (FDA) has approved vaccines designed by GSK, Pfizer and Moderna to protect high-risk populations against respiratory syncytial virus (RSV). …”
Get full text
Article -
132
-
133
Estudio de reactogenicidad en las vacunas mRNA frente a la COVID-19
Published 2023-04-01“… Objetivo: Comparar la reactogenicidad entre los tipos de vacuna RNAm Commirnaty® (Pfizer) y Spikevax® (Moderna) frente a la COVID-19 en población sanitaria. …”
Get full text
Article -
134
-
135
Estudio de reactogenicidad en las vacunas mRNA frente a la COVID-19
Published 2023-04-01“… Objetivo: Comparar la reactogenicidad entre los tipos de vacuna RNAm Commirnaty® (Pfizer) y Spikevax® (Moderna) frente a la COVID-19 en población sanitaria. …”
Get full text
Article -
136
S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines
Published 2025-01-01“…Additionally, the effectiveness of RV-1730 as a heterologous booster following primary vaccination with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna-NIAID) was assessed.ResultsRV-1730 elicited significantly stronger B and T cell responses and more durable neutralizing antibodies compared to S2P-based vaccines. …”
Get full text
Article -
137
-
138
Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)
Published 2025-01-01“…The vaccines administered in the last dose were Biontech/Pfizer and Moderna in 88.6% of the cases. 59.5% of sample had suffered from COVID-19 and 67.0% did not have any clinical comorbidity. …”
Get full text
Article -
139
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination
Published 2025-01-01“…IntroductionThe durability of Hybrid immunity induced by natural infection and/or COVID-19 vaccines and evidence supporting further booster vaccination are crucial factors for pandemic response, yet remain poorly understood.MethodsWe measured the durability of immune response and neutralizing capacity of antibodies following Homologous/Heterologous vaccination by mRNA-based vaccines (Pfizer-BioNTech BNT162b2) or (Moderna mRNA-1273) and viral vector-based vaccines (ChAdox1 nCoV-19-Oxford-AstraZeneca) in infected and non-infected patients. …”
Get full text
Article -
140